Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0YV4F
|
||||
| Former ID |
DCL000581
|
||||
| Drug Name |
Ocrelizumab
|
||||
| Synonyms |
Ocrelizumab (USAN); Ocrelizumab (genetical recombination); Ocrelizumab (genetical recombination) (JAN)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Relapsing or primary progressive forms of multiple sclerosis [ICD10:G35] | Approved | [889446] | ||
| Company |
Genentech
|
||||
| CAS Number |
CAS 637334-45-3
|
||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | [536651], [551607] | ||
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.